Effectiveness of mechanical circulatory support devices in reversing pulmonary hypertension among heart transplant candidates: A systematic review.

• MCS Device Efficacy: MCS devices, particularly LVADs, are effective in reducing pulmonary vascular resistance and reversing fixed pulmonary hypertension, enhancing transplant eligibility. • Improved Transplant Prospects: Utilization of MCS devices correlates with increased transplant eligibility and potentially improved post-transplant survival rates. • Need for Further Research: The manuscript emphasizes the necessity for additional comparative research to fine-tune the application and selection of MCS devices for patients with fixed pulmonary hypertension. • Global Perspective: The study offers valuable insights from a global dataset, underscoring the importance and evolving utility of MCS devices in heart transplant medicine over recent decades. • Comprehensive Analysis: This manuscript presents a detailed systematic review, providing a robust synthesis of the impact of MCS devices on the management of fixed pulmonary hypertension in heart transplant candidates. Pulmonary hypertension (PH) poses a significant challenge in the selection of candidates for heart transplantation, impacting their eligibility and post-transplant outcomes. Mechanical circulatory support (MCS) devices, particularly left ventricular assist devices (LVADs), have emerged as a therapeutic option to manage PH in this patient population. This systematic review aims to evaluate the effectiveness of MCS devices in reversing fixed pulmonary hypertension in heart transplant candidates. A comprehensive literature search was conducted across multiple databases, including PubMed, Scopus, and Web of Science, to identify studies that evaluated the effectiveness of MCS devices in reversing fixed pulmonary hypertension in heart transplant candidates. Data on pulmonary vascular resistance, PH reversal, heart transplant eligibility, and post-transplant outcomes were extracted and synthesized. The review included studies that demonstrated the potential of MCS devices, especially LVADs, to significantly reduce pulmonary vascular resistance and reverse fixed pulmonary hypertension in heart transplant candidates. These findings suggest that MCS devices can improve transplant eligibility and may positively impact post-transplant survival rates. However, the literature also indicates a need for further comparative studies to optimize MCS device selection and treatment protocols. MCS devices, particularly LVADs, play a crucial role in the management of fixed pulmonary hypertension in heart transplant candidates, improving their eligibility for transplantation and potentially enhancing post-transplant outcomes. Future research should focus on comparative effectiveness studies to guide clinical decision-making and optimize patient care in this challenging clinical scenario. [ABSTRACT FROM AUTHOR]